We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program
News

MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program

MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program
News

MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced today it will receive a milestone payment from Centocor Ortho Biotech Inc. in connection with the initiation of a Phase 1 clinical trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

"The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Progress in the development of innovative biopharmaceutical agents by our partners is a key driver of our company's growth."

The current program becomes the second HuCAL antibody derived from MorphoSys's collaboration with Centocor Ortho Biotech Inc. to enter the clinic.

In 2007, Centocor Ortho Biotech Inc. started a Phase 1 study with a HuCAL antibody in oncology patients and commenced a Phase 2 trial in an immunological indication using the same antibody one year later. The antibody became the first from MorphoSys to be developed in two different indications. With the new study, Centocor Ortho Biotech Inc. will be running three clinical trials of HuCAL antibodies.
Advertisement